Results 31 to 40 of about 197,741 (365)

Varying Cellular Immune Response against SARS-CoV-2 after the Booster Vaccination: A Cohort Study from Fukushima Vaccination Community Survey, Japan

Vaccines, 2023
Booster vaccination reduces the incidence of severe cases and mortality related to COVID-19, with cellular immunity playing an important role. However, little is known about the proportion of the population that has achieved cellular immunity after ...
Yuta Tani, Morihito Takita, Yurie Kobashi, Masatoshi Wakui, Tianchen Zhao, Chika Yamamoto, Hiroaki Saito, Moe Kawashima, Sota Sugiura, Yoshitaka Nishikawa, Fumiya Omata, Yuzo Shimazu, Takeshi Kawamura, Akira Sugiyama, Aya Nakayama, Yudai Kaneko, Tetsuhiko Kodama, Masahiro Kami, Masaharu Tsubokura   +18 more
doaj   +1 more source

BNT162b2 Vaccine Booster and Mortality Due to Covid-19

New England Journal of Medicine, 2021
Background The emergence of the B.1.617.2 (delta) variant of severe acute respiratory syndrome coronavirus 2 and the reduced effectiveness over time of the BNT162b2 vaccine (Pfizer–BioNTech) led to a resurgence of coronavirus disease 2019 (Covid-19 ...
R. Arbel, A. Hammerman, R. Sergienko, M. Friger, Alon Peretz, D. Netzer, S. Yaron   +6 more
semanticscholar   +1 more source

Efficacy of the Second COVID-19 Vaccine Booster Dose in the Elderly

Vaccines, 2023
Background: We analyzed coronavirus disease 2019 (COVID-19) vaccine efficacy in older persons who received the second booster compared to unvaccinated people and those receiving only a single COVID-19 vaccine booster. Methods: We collected information on
Camilla Mattiuzzi, Giuseppe Lippi
doaj   +1 more source

Humoral and T Cell Immune Responses against SARS-CoV-2 after Primary and Homologous or Heterologous Booster Vaccinations and Breakthrough Infection: A Longitudinal Cohort Study in Malaysia

Viruses, 2023
Vaccine efficacy against SARS-CoV-2 could be compromised by the emergence of SARS-CoV-2 variants and it is important to study how it impacts the booster vaccination regime.
Jolene Yin Ling Fu, Muhammad Harith Pukhari, Maria Kahar Bador, I-Ching Sam, Yoke Fun Chan   +4 more
doaj   +1 more source

Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster

New England Journal of Medicine, 2022
To the Editor: The emergence of the highly divergent B.1.1.529 (omicron) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) led to concerns about the efficacy of vaccines based on the ancestral spike and to the approval in the United
Meredith E. Davis-Gardner, L. Lai, Bushra Wali, Hady Samaha, D. Solis, Matthew Lee, Andrea Porter-Morrison, I. T. Hentenaar, F. Yamamoto, Sucheta Godbole, Yuan Liu, D. Douek, F. Lee, N. Rouphael, Alberto Moreno, B. Pinsky, M. Suthar   +16 more
semanticscholar   +1 more source

Durability of immune responses to mRNA booster vaccination against COVID-19

Journal of Clinical Investigation, 2023
Background Maintaining durable immunity following vaccination represents a major challenge, but whether mRNA booster vaccination improves durability is unknown.
P. Arunachalam, L. Lai, Hady Samaha, Yupeng Feng, Mengyun Hu, Harold Hui, Bushra Wali, M. Ellis, Meredith E. Davis-Gardner, C. Huerta, Kareem Bechnak, Sarah Bechnak, Matthew Lee, Matthew B. Litvack, C. Losada, A. Grifoni, A. Sette, V. Zarnitsyna, N. Rouphael, M. Suthar, B. Pulendran   +20 more
semanticscholar   +1 more source

COVID-19 Vaccine Booster Strategies for Omicron SARS-CoV-2 Variant: Effectiveness and Future Prospects

Vaccines, 2022
In the light of the lack of authorized COVID-19 vaccines adapted to the Omicron variant lineage, the administration of the first and second booster dose is recommended.
Dorota Zarębska-Michaluk, Chenlin Hu, Michał Brzdęk, Robert Flisiak, Piotr Rzymski   +4 more
doaj   +1 more source

Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study

Lancet Global Health, 2022
Background Several countries have authorised or begun using a booster vaccine dose against COVID-19. Policy makers urgently need evidence of the effectiveness of additional vaccine doses and its clinical spectrum for individuals with complete primary ...
A. Jara, E. Undurraga, J. Zubizarreta, C. González, A. Pizarro, Johanna Acevedo, Katherinne Leo, F. Paredes, Tomás Bralic, V. Vergara, Marcelo Mosso, Francisco Leon, Ignacio Parot, Paulina Leighton, P. Suárez, J. C. Ríos, Heriberto E. García-Escorza, R. Araos   +17 more
semanticscholar   +1 more source

Evaluating COVID-19 Booster Vaccination Strategies in a Partially Vaccinated Population: A Modeling Study

Vaccines, 2022
Background: Several countries are implementing COVID-19 booster vaccination campaigns. The objective of this study was to model the impact of different primary and booster vaccination strategies.
Clément R. Massonnaud, Jonathan Roux, Vittoria Colizza, Pascal Crépey   +3 more
doaj   +1 more source

Comparative effectiveness of bivalent BA.4-5 and BA.1 mRNA booster vaccines among adults aged ≥50 years in Nordic countries: nationwide cohort study

British medical journal, 2023
Objective To estimate the effectiveness of the bivalent mRNA booster vaccines containing the original SARS-CoV-2 and omicron BA.4-5 or BA.1 subvariants as the fourth dose against severe covid-19.
N. Andersson, E. M. Thiesson, U. Baum, Nicklas Pihlström, J. Starrfelt, K. Faksová, E. Poukka, H. Meijerink, R. Ljung, A. Hviid   +9 more
semanticscholar   +1 more source